RecruitingNASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

Eligible age

18–80 yrs

Accepts

All genders

Locations

34 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

Sponsor: Akero Therapeutics, Inc

You may qualify if…

✓ Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH and NAS score of \>=3 (at least 1 in each category) or evidence of steatosis and 2 current features of metabolic comorbidities
✓ Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH

You may not qualify if…

✕ Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results
✕ Type 1 diabetes or unstable Type 2 diabetes
✕ Any current or prior history of decompensated liver disease
✕ Other inclusion and exclusion criteria may apply.